1,721,071 research outputs found
Dramatic development of severe SLE in a patient with an incomplete disease
No full textThis case report describes the previously-unreported clinical course of a patient with a so-called incomplete systemic lupus erythematosus (SLE), i.e. symptoms related to one organ system only, together with the presence of ANA. He had an indolent course initially and developed, 6 months after the first symptoms, a severe disease with rapid appearance of major and unusual manifestations. The possibility of fast progression and a grave course of an incomplete SLE should be kept in mind. This report is meant to heighten awareness of such an atypical presentation so that prompt and aggressive immunosuppressive therapy may be instituted. (copyright) Springer-Verlag 2005
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
CAP, HCAP and immunocompromised patients with pneumonia : should we rethink the concepts?
No full text
Community acquired and health-care associated pneumonia : should we own follow guidelines?
No full textTreatment of healthcare-associated pneumonia (HCAP) according to published guidelines recommend initial broad-spectrum antibiotics and de-escalation based on culture results.
This study aims to investigate the in-hospital and 30-day mortality and LOS in both CAP and HCAP non-immunocompromised (NIC) and HCAP immunocompromised (IC) related to the empirical antibiotic therapy started at admission, before microbiological data availability.
All patients admitted to a university tertiary care hospital in Milan with a diagnosis of pneumonia from 2005 to 2011 were prospectical enrolled. CAP, HCAP and immunocompromised were identified on the basis of the existing criteria. Therapies of two periods (T1: 2005-2007 and T2: 2010-2011) have been compared.
Ongoing Results
A total of 275 patients, 135 HCAP, were included in the analysis. T1 accounted for 240 CAP, 40 HCAP-NIC and 80 HCAP-IC. T2 (partial results) accounted for 20 CAP, 4 HCAP-NIC, 11 CAP-IC.
During T1, culture positive were 23.3% and culture negative 55%. The majority of CAP was started with monotherapy (51.7%), while the most of HCAP with dual-therapy (NIC 45%, IC 41.3%). Triple-therapy was addressed for 9.2% of CAP, 12.5% of HCAP-NIC and 25.0% of HCAP-IC.
During T2, culture positive were 17.1% and culture negative 80%. The majority of CAP and HCAP-IC started a dual-therapy (55% and 54.5%), while 50% of HCAP-NIC had a monotherapy. Triple-therapy was started in 5% of CAP, 25% of HCAP-NIC and 18.2% of HCAP-IC.
In CAP of both periods none of the patients treated with triple-therapy died, and there were no differences for mortality between mono and dual-therapy. HCAP with dual therapy had less mortality than both monotherapy and triple-therapy
- …
